A randomized, open-label, multicenter study of switching to brolucizumab with or without a loading dose for patients with suboptimal anatomically controlled neovascular age-related...

por Holz, F. G., Schmitz-Valckenberg, Steffen, Wolf, A., Agostini, H., Lorenz, K., Pielen, A., Feltgen, N., Guthoff, R., Quiering, C., Clemens, A., Jaeger, K.
Publicado 2022